Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: Temporal and spatial pattern of mass vs. strength response

Journal of Inherited Metabolic Disease

Volumn 33, Issue 6, 2010, Pages 737-745

  Ravaglia, Sabrina ^a   Pichiecchio, Anna ^b   Ponzio, Michela ^a   Danesino, Cesare ^a   Garaghani, Kolsoum Saeidi ^a   Poloni, Guy Umberto ^b   Toscano, Antonio ^c   Moglia, Arrigo ^a   Carlucci, Annalisa ^d   Bini, Paola ^a   Ceroni, Mauro ^a   Bastianello, Stefano ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BODY FAT; BODY MASS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONTROLLED STUDY; DYNAMOMETRY; EARLY INTERVENTION; ENZYME REPLACEMENT; FEMALE; FOLLOW UP; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LEAN BODY WEIGHT; LIPID STORAGE; MALE; MUSCLE EXAMINATION; MUSCLE MASS; MUSCLE STRENGTH; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; SKELETAL MUSCLE; TREATMENT RESPONSE; AGED; ANIMAL; CHO CELL; CLINICAL TRIAL; CRICETULUS; DRUG EFFECT; HAMSTER; HISTOLOGY; METABOLISM; MIDDLE AGED; ORGAN SIZE; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; AGED; ALPHA-GLUCOSIDASES; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME REPLACEMENT THERAPY; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MIDDLE AGED; MUSCLE STRENGTH; MUSCLE, SKELETAL; ORGAN SIZE; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952564454     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-010-9204-5     Document Type: Article

References (22)

1. Bohannon RW (1997) Reference values for extremity muscle strength obtained by hand-held dynamometry from adults aged 20 to 79 years. Arch Phys Med Rehabil 78:26-32
2. Enright PL, Sherrill DL (1998) Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 158(5 Pt 1):1384-1387 (Pubitemid 28536595)
3. Fukuda T, Ahearn M, Roberts A et al. (2006) Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol Ther 14(6):831-839 (Pubitemid 44743133)
4. Gerrits KH, Beltman MJ, Koppe PA et al. (2009) Isometric muscle function of knee extensors and the relation with functional performance in patients with stroke. Arch Phys Med Rehabil 90:480-487
5. Hagemans ML, Winkel LP, Van Doorn PA et al. (2005) Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 128(Pt 3):671-677 (Pubitemid 40380201)
6. Jankowska EA, Wegrzynowska K, Superlak M et al. (2008) The 12-week progressive quadriceps resistance training improves muscle strength, exercise capacity and quality of life in patients with stable chronic heart failure. Int J Cardiol 130 (1):36-43
7. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D (2006) Infantile-Onset Pompe Disease Natural History Study Group. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148 (5):671-676
8. Kobayashi H, Shimada Y, Ikegami M et al. (2010) Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case. Mol Genet Metab 100(1):14-19
9. Laaban JP, Kouchakji B, Dore MF, Orvoen-Frija E, David P, Rochemaure J (1993) Nutritional status of patients with chronic obstructive pulmonary disease and acute respiratory failure. Chest 103(5):1362-1368 (Pubitemid 23145585)
10. Luden N, Minchev K, Hayes E, Louis E, Trappe T, Trappe S (2008) Human vastus lateralis and soleus muscles display divergent cellular contractile properties. Am J Physiol Regul Integr Comp Physiol 295:R1593-R1598
11. Lynch NA, Metter EJ, Lindle RS et al. (1999) Muscle quality. I. Ageassociated differences between arm and leg muscle groups. J Appl Physiol 86:188-194 (Pubitemid 29046957)
12. Merk T, Wibmer T, Schumann C, Krüger S (2009) Glycogen storage disease type II (Pompe disease)-influence of enzyme replacement therapy in adults. Eur J Neurol 16:274-277
13. Pichiecchio A, Poloni GU, Ravaglia S et al. (2009) Enzyme replacement therapy in adult-onset glycogenosis II: is quantitative muscle MRI helpful? Muscle Nerve 40(1):122-125
14. Ravaglia S, Danesino C, Pichiecchio A et al. (2008) Enzyme replacement therapy in severe adult-onset glycogen storage disease type II. Adv Ther 25(8):820-829
15. Ravaglia S, Moglia A, Costa A, Repetto A, Danesino C (2009) Enzyme replacement therapy in late-onset type II glycogenosis. Eur J Neurol 16(7):e125
16. Ravaglia S, Danesino C, Moglia A et al. (2010) Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis. Eur J Neurol 17:957-962
17. Rohrbach M, Clarke JT (2007) Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 67:2697-2716 (Pubitemid 350224380)
18. Slonim AE, Bulone L, Goldberg T et al. (2007) Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve 35:70-77 (Pubitemid 46052651)
19. Strothotte S, Strighl-Pill N, Grunert B et al. (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91-97
20. van den Hout JM, Kamphoven JH, Winkel LP et al. (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448-e457
21. van der Ploeg RJ, Fidler V, Oosterhuis HJ (1991) Hand-held myometry: reference values. J Neurol Neurosurg Psychiatry 54 (3):244-247
22. van der Ploeg AT, Clemens PR, Corzo D et al. (2010) A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 362(15):1396-1406